Impact of tumor volume on outcomes in patients with locally advanced non-small cell lung cancer receiving chemoradiotherapy and consolidation durvalumab.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
92 patients (median follow-up: 28.
I · Intervention 중재 / 시술
concurrent CRT, typically cisplatin-based (60%)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Smaller PTV was independently associated with longer PFS, supporting its value in personalized care for LA-NSCLC. [ADVANCES IN KNOWLEDGE] PTV emerged as an independent prognostic factor for PFS, suggesting its utility in risk stratification and individualized treatment planning.
[INTRODUCTION] The standard of care for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by consolidation immunotherapy.
- p-value p = 0.01
- p-value p = 0.047
- HR 0.45
- 추적기간 28.9 months
APA
Legendre V, Botticella A, et al. (2026). Impact of tumor volume on outcomes in patients with locally advanced non-small cell lung cancer receiving chemoradiotherapy and consolidation durvalumab.. The British journal of radiology. https://doi.org/10.1093/bjr/tqag048
MLA
Legendre V, et al.. "Impact of tumor volume on outcomes in patients with locally advanced non-small cell lung cancer receiving chemoradiotherapy and consolidation durvalumab.." The British journal of radiology, 2026.
PMID
41834097 ↗
Abstract 한글 요약
[INTRODUCTION] The standard of care for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by consolidation immunotherapy. We analysed clinical, biological, and dosimetric data to identify survival predictors and inform personalized treatment strategies.
[METHODS] We retrospectively reviewed LA-NSCLC patients treated between December 2015 and January 2023. Data were extracted from electronic medical records. Progression-free survival (PFS) and overall survival (OS) were calculated from diagnosis. Kaplan-Meier estimates and Cox proportional hazards models were used for survival analysis.
[RESULTS] We included 92 patients (median follow-up: 28.9 months); 66% were male, 60% former smokers, and the median age was 64. Stage IIIB (50%) and adenocarcinoma (60%) were most common. PD-L1 positivity was observed in 75%, and 27% had oncogenic drivers (KRAS: 24%, EGFR: 3%). Most (86%) received concurrent CRT, typically cisplatin-based (60%). Median durvalumab duration was 9.5 months. Median PFS and OS were 31.9 and 51.2 months, respectively. Recurrence was locoregional (15%) or metastatic (60% oligometastatic, 25% polymetastatic). PFS was longer in patients aged <66 years (45.4 vs. 16.0 months; p = 0.01), with pre-RT lymphocyte counts >1.80 G/L (45.4 vs. 27.7 months; p = 0.047), or PTV <450 cc (44.3 vs. 16.1 months; p = 0.01). On multivariate analysis, only PTV <450 cc remained significant (HR: 0.45; p = 0.04). No factor was associated with OS in multivariable analysis.
[CONCLUSIONS] Smaller PTV was independently associated with longer PFS, supporting its value in personalized care for LA-NSCLC.
[ADVANCES IN KNOWLEDGE] PTV emerged as an independent prognostic factor for PFS, suggesting its utility in risk stratification and individualized treatment planning.
[METHODS] We retrospectively reviewed LA-NSCLC patients treated between December 2015 and January 2023. Data were extracted from electronic medical records. Progression-free survival (PFS) and overall survival (OS) were calculated from diagnosis. Kaplan-Meier estimates and Cox proportional hazards models were used for survival analysis.
[RESULTS] We included 92 patients (median follow-up: 28.9 months); 66% were male, 60% former smokers, and the median age was 64. Stage IIIB (50%) and adenocarcinoma (60%) were most common. PD-L1 positivity was observed in 75%, and 27% had oncogenic drivers (KRAS: 24%, EGFR: 3%). Most (86%) received concurrent CRT, typically cisplatin-based (60%). Median durvalumab duration was 9.5 months. Median PFS and OS were 31.9 and 51.2 months, respectively. Recurrence was locoregional (15%) or metastatic (60% oligometastatic, 25% polymetastatic). PFS was longer in patients aged <66 years (45.4 vs. 16.0 months; p = 0.01), with pre-RT lymphocyte counts >1.80 G/L (45.4 vs. 27.7 months; p = 0.047), or PTV <450 cc (44.3 vs. 16.1 months; p = 0.01). On multivariate analysis, only PTV <450 cc remained significant (HR: 0.45; p = 0.04). No factor was associated with OS in multivariable analysis.
[CONCLUSIONS] Smaller PTV was independently associated with longer PFS, supporting its value in personalized care for LA-NSCLC.
[ADVANCES IN KNOWLEDGE] PTV emerged as an independent prognostic factor for PFS, suggesting its utility in risk stratification and individualized treatment planning.